Browse Drug Recalls
1,034 FDA drug safety recalls.
FDA Drug Recall Enforcement Database
Browse 1,034 FDA drug recall enforcement actions. Each entry includes the product description, reason for recall, classification (Class I through III based on severity), recalling firm, and distribution details. Use the filters below to search by year, classification, state, or keyword.
Drug Safety Recalls
Browse 1,034 FDA drug recalls in NY.
| Date | Product | Reason | Class | Firm |
|---|---|---|---|---|
| May 20, 2024 | Labetalol Hydrochloride Injection, USP, 20 mg/4 mL (5 mg/mL), 4 mL Single-dos... | Lack of Assurance of Sterility-The potential for incomplete crimp seals. | Class II | Pfizer Inc. |
| May 15, 2024 | EYLEA, (aflibercept) Injection, For Intravitreal injection, 2 mg (0.05mL of a... | Lack of Assurance of Sterility: Complaints of syringe breakage | Class II | Regeneron Pharmaceuticals Inc |
| Apr 23, 2024 | EYLEA, (aflibercept) Injection, 2 mg (0.05mL of a 40mg/mL solution), Single-d... | Lack of Assurance of Sterility: Complaints of syringe breakage | Class II | Regeneron Pharmaceuticals Inc |
| Apr 2, 2024 | Cyclophosphamide for Injection, USP, 500mg/vial, Lyophilized, Cytotoxic Agent... | Labeling: Incorrect or missing Package Insert: There is an error on the Package Insert (PI), sect... | Class III | X-Gen Pharmaceuticals Inc. |
| Apr 2, 2024 | Cyclophosphamide for Injection, USP, 1g/vial, Lyophilized, Single Dose Vial, ... | Labeling: Incorrect or missing Package Insert: There is an error on the Package Insert (PI), sect... | Class III | X-Gen Pharmaceuticals Inc. |
| Mar 25, 2024 | Methylergonovine Maleate Tablets, USP, 0.2mg, 12-count bottle, Rx Only, Distr... | Failed Dissolution Specifications | Class II | Amneal Pharmaceuticals of New York, LLC |
| Mar 21, 2024 | Vancomycin Hydrochloride for Oral Solution, USP, 250 mg per 5 mL, packaged as... | Superpotent Drug: Due to overfilling of drug powder | Class I | Amneal Pharmaceuticals of New York, LLC |
| Mar 21, 2024 | VCF Vaginal Contraceptive Film (nonoxynol-9, 28%), package in a carton with 9... | cGMP Diviations | Class II | Apothecus Pharmaceutical Corp. |
| Feb 13, 2024 | Oseltamivir Phosphate for Oral Suspension 6mg/ml, 60 mL (reconstituted) bottl... | Failed Impurities/Degradation Specifications: Out-of-specification test results. | Class II | Amneal Pharmaceuticals of New York, LLC |
| Feb 12, 2024 | ForeverMen Natural Energy Boost Capsules, packaged in a box containing a 10-c... | Marketed Without an Approved NDA/ANDA: Product was found to contain undeclared sildenafil, an ing... | Class I | FA Online Inc |
| Feb 5, 2024 | Neptune's Fix, Tianeptine Elixir, Fast Acting, 0.338 fl.oz. (10 mL) bottle, D... | Marketed without an approved NDA/ANDA: Product contains tianeptine, a substance not FDA-approved ... | Class I | Super Chill Products |
| Feb 1, 2024 | TING 1% Tolnaftate Athlete's Foot Spray Antifungal Spray Liquid, NET WT 4.5 o... | Chemical Contamination; presence of benzene. | Class I | Insight Pharmaceuticals LLC, a Prestige Consume... |
| Jan 17, 2024 | Adrenalin (epinephrine) Injection 1mg/mL, 1mL single dose vial, Rx only, Pack... | Labeling: Incorrect or Missing Lot and/or Exp Date. The expiration date listed on the Repack Pouc... | Class II | Henry Schein Inc. and Glove Club HSI Gloves Inc. |
| Jan 15, 2024 | Phenoxybenzamine Hydrochloride Capsules, USP 10mg, 100-count bottle, Rx only,... | Failed Impurities/Degradation Specifications: Out of specification for unknown impurity. | Class II | Amneal Pharmaceuticals of New York, LLC |
| Dec 28, 2023 | Premier Value Tussin Cough DM, Dextromethorphan HBr...Cough Suppressant, Guai... | CGMP Deviations: Firm reported possible microbial contamination in the purified water used in the... | Class II | Seaway Pharma Inc. |
| Dec 28, 2023 | Quality Choice No Drip Severe Congestion Nasal Pump Mist, Oxymetazoline hydro... | CGMP Deviations: Firm reported possible microbial contamination in the purified water used in the... | Class II | Seaway Pharma Inc. |
| Dec 28, 2023 | Nasal Spray Original No Drip Oxymetazoline HCl Nasal Solution, 12 Hour Pump M... | CGMP Deviations: Firm reported possible microbial contamination in the purified water used in the... | Class II | Seaway Pharma Inc. |
| Dec 28, 2023 | Quality Choice No Drip Extra Moisturizing Nasal Pump Mist Oxymetazoline hydro... | CGMP Deviations: Firm reported possible microbial contamination in the purified water used in the... | Class II | Seaway Pharma Inc. |
| Dec 26, 2023 | Divalproex Sodium Extended-release Tablets, USP 250 mg, Rx Only, 100 tablets,... | Failed dissolution specifications | Class II | Amneal Pharmaceuticals of New York, LLC |
| Dec 21, 2023 | Atropine Sulfate Injection, USP 1 mg/10 mL (0.1 mg/mL), Lifeshield, Glass ABB... | Presence of Particulate Matter; identified as glass | Class I | Pfizer Inc. |
| Dec 21, 2023 | Americaine, (benzocaine 20%) Benzocaine Topical Anesthetic Spray, Aerosol Can... | Chemical Contamination: presence of benzene | Class I | Insight Pharmaceuticals LLC, a Prestige Consume... |
| Dec 21, 2023 | 8.4 % Sodium Bicarbonate Injection, USP 50 mEq/50 mL (1 mEq/mL), Lifeshield, ... | Presence of Particulate Matter; identified as glass | Class I | Pfizer Inc. |
| Dec 21, 2023 | Bleomycin for Injection, USP, 15 units per vial, 1 single dose glass fliptop ... | Presence of particulate matter: glass | Class I | PFIZER |
| Dec 21, 2023 | 4.2% Sodium Bicarbonate Injection, USP 5 mEq/10 mL (0.5 mEq/mL), Glass ABBOJE... | Presence of Particulate Matter; identified as glass | Class I | Pfizer Inc. |
| Nov 29, 2023 | Magnum XXL 9800, 2000 mg per capsule, 1 capsule per blister pack, Distributed... | Marketed without an approved NDA/ANDA: Magnum XXL found to contain undeclared active pharmaceutic... | Class I | Meta Herbal |
| Nov 17, 2023 | Vigabatrin for Oral Solution, USP 500 mg per packet, 50 packets per box, Rx O... | Defective Container: powder may leak out of the pouch | Class I | InvaGen Pharmaceuticals, Inc. |
| Oct 27, 2023 | Extended Phenytoin Sodium Capsules, USP, 100 mg, 100-count bottle, Distribute... | Failed Dissolution Specifications | Class II | Amneal Pharmaceuticals of New York, LLC |
| Oct 2, 2023 | 1% Lidocaine HCl Injection, USP, 50mg/5mL(10mg/mL), Glass ABBOJECT Unit of Us... | Presence of Particulate Matter: identified as glass. | Class I | Pfizer Inc. |
| Oct 2, 2023 | Tropi-Phen (Tropicamide 1% phenylephrine HCl 2.5%) ophthalmic solution, 15 mL... | Lack of Assurance of Sterility | Class II | Pine Pharmaceuticals, LLC |
| Oct 2, 2023 | Foscarnet Sodium 2.4mg/0.1 mL solution for injection, 0.2 mL single-dose Sta... | Lack of Assurance of Sterility | Class II | Pine Pharmaceuticals, LLC |
| Oct 2, 2023 | Endophth Kit (Vancomycin 1mg/0.1 mL - Ceftazidime 2.25mg/0.1 mL), Rx only, Co... | Lack of Assurance of Sterility | Class II | Pine Pharmaceuticals, LLC |
| Oct 2, 2023 | Bevacizumab 1.25 MG/0.05 ML Solution for Injection, 1 mL syringes, Rx only, C... | Lack of Assurance of Sterility | Class II | Pine Pharmaceuticals, LLC |
| Oct 2, 2023 | Tropi-Phen (tropicamide 1%, phenylephrine 2.5%) ophthalmic solution, 5mL mult... | Lack of Assurance of Sterility | Class II | Pine Pharmaceuticals, LLC |
| Oct 2, 2023 | Vancomycin 1 MG/0.1 ML Solution for Intraocular Injection, 0.8 ML Single Dose... | Lack of Assurance of Sterility | Class II | Pine Pharmaceuticals, LLC |
| Oct 2, 2023 | Calcium Gluconate 2.5% solution for inhalation, 5mL pre-filled syringes, Rx o... | Lack of Assurance of Sterility | Class II | Pine Pharmaceuticals, LLC |
| Oct 2, 2023 | Lidocaine HCL 2% and Oxymetazoline HCl 0.025% Solution for intranasal adminis... | Lack of Assurance of Sterility | Class II | Pine Pharmaceuticals, LLC |
| Oct 2, 2023 | Calcium Gluconate Ophthalmic Irrigation Solution 1%, 500 mL bags, Rx only, C... | Lack of Assurance of Sterility | Class II | Pine Pharmaceuticals, LLC |
| Oct 2, 2023 | 4.2% Sodium Bicarbonate Injection, USP 5 mEq/10 mL (0.5mEq/mL), Glass ABBOJEC... | Presence of Particulate Matter: identified as glass. | Class I | Pfizer Inc. |
| Oct 2, 2023 | TPC Drops (tropicamide 1%- phenylephrine 2.5%- cyclopentolate HCl 1% ophthalm... | Lack of Assurance of Sterility | Class II | Pine Pharmaceuticals, LLC |
| Oct 2, 2023 | Moxifloxacin in Balanced Salt Solution, Solution for Intraocular Injection, 6... | Lack of Assurance of Sterility | Class II | Pine Pharmaceuticals, LLC |
| Oct 2, 2023 | Lidocaine HCl 4% ophthalmic solution, 3 mL single-use dropper, Rx only, Compo... | Lack of Assurance of Sterility | Class II | Pine Pharmaceuticals, LLC |
| Oct 2, 2023 | 2% Lidocaine HCl Injection, USP, 100mg/5mL(20mg/mL), Glass ABBOJECT Unit of U... | Presence of Particulate Matter: identified as glass. | Class I | Pfizer Inc. |
| Oct 2, 2023 | Calcium chloride Solution for Intravenous Injection, 20 mg/mL, 500 mL bags, R... | Lack of Assurance of Sterility | Class II | Pine Pharmaceuticals, LLC |
| Oct 2, 2023 | Moxifloxacin in Balanced Salt Solution 400 mcg/0.4 mL (100 mcg/0.1 mL) 1 mL s... | Lack of Assurance of Sterility | Class II | Pine Pharmaceuticals, LLC |
| Oct 2, 2023 | Cefuroxime 4mg /0.4 mL (10 mg/mL), 1mL syringe, Rx only, Compounded by: Pine ... | Lack of Assurance of Sterility | Class II | Pine Pharmaceuticals, LLC |
| Oct 2, 2023 | Lidocaine-phenylephrine 1%-1.5% 1mL Single Dose Vial, Rx only, Compounded by ... | Lack of Assurance of Sterility | Class II | Pine Pharmaceuticals, LLC |
| Aug 25, 2023 | WEFUN Capsules 825 mg, 1x10 blister pack per carton, Manufactured by WEFUN Br... | Marketed Without an Approved NDA/ANDA: FDA analysis found the product to be tainted with sildenaf... | Class I | Hua Da Trading, Inc. dba Wefun Inc. |
| Jul 7, 2023 | Norepinephrine 32 mg per 250 mL (128 mcg per mL) in 0.9% Sodium Chloride, 250... | Lack of Assurance of Sterility | Class II | SterRx, LLC |
| Jul 7, 2023 | Norepinephrine 8 mg per 250 mL (32 mcg per mL) in 0.9% Sodium Chloride, 250 m... | Lack of Assurance of Sterility | Class II | SterRx, LLC |
| Jul 7, 2023 | Norepinephrine 16 mg per 250 mL (64 mcg per mL) in 0.9% Sodium Chloride, 250 ... | Lack of Assurance of Sterility | Class II | SterRx, LLC |
Frequently Asked Questions
When a drug safety issue is identified, through FDA inspections, laboratory testing, adverse event reports, or manufacturer quality checks, the responsible company issues a recall to remove the affected products from the market. Pharmacies pull the product from shelves, and consumers are advised to contact their healthcare provider for alternatives.
The leading causes include cGMP deviations, impurity contamination (including nitrosamines like NDMA), failed dissolution or stability testing, sterility issues, potency problems, labeling errors, and foreign particle contamination.
Use the search and filter tools on this page to look up specific medications, active ingredients, or manufacturers. Each recall entry includes the product description, lot numbers, and distribution details.